WallStSmart

Atea Pharmaceuticals Inc (AVIR)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 216% more annual revenue ($606.42M vs $192.18M). AVIR leads profitability with a 0.0% profit margin vs -2.1%. AVIR earns a higher WallStSmart Score of 54/100 (C-).

AVIR

Buy

54

out of 100

Grade: C-

Growth: 4.3Profit: 3.0Value: 5.0Quality: 8.5
Piotroski: 2/9Altman Z: 8.97

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AVIR3 strengths · Avg: 9.3/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
8.9710/10

Safe zone — low bankruptcy risk

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

AVIR4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
3.0%4/10

3.0% revenue growth

EPS GrowthGrowth
2.6%4/10

2.6% earnings growth

Market CapQuality
$450.94M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : AVIR

The strongest argument for AVIR centers on Debt/Equity, Altman Z-Score, Price/Book.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : AVIR

The primary concerns for AVIR are Revenue Growth, EPS Growth, Market Cap.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

AVIR profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

AVIR is growing revenue faster at 3.0% — sustainability is the question.

AVIR generates stronger free cash flow (-28M), providing more financial flexibility.

Bottom Line

AVIR scores higher overall (54/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Atea Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.

Visit Website →

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?